mazindol has been researched along with Benign Neoplasms in 2 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruera, E | 2 |
| MacDonald, RN | 1 |
| Carraro, S | 1 |
| Roca, E | 1 |
| Barugel, M | 1 |
| Chacon, R | 1 |
1 trial available for mazindol and Benign Neoplasms
| Article | Year |
|---|---|
Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
Topics: Anxiety; Appetite; Clinical Trials as Topic; Depression; Female; Humans; Indoles; Male; Mazindol; Mi | 1986 |
1 other study available for mazindol and Benign Neoplasms
| Article | Year |
|---|---|
Overwhelming fatigue in advanced cancer.
Topics: Asthenia; Humans; Mazindol; Methylphenidate; Methylprednisolone; Neoplasms | 1988 |